Frequent allelic losses on chromosome 22q in small cell lung carcinomas (SCLCs) and advanced non-small cell lung carcinomas indicate the presence of tumor suppressor gene(s) on this chromosome arm. We detected a homozygous deletion at 22q12.1 in a SCLC cell line, Lu24. Cloning of the breakpoints of the Lu24 deletion revealed that the deletion was interstitial and 428, 131 bp in size. The deleted region contained the SEZ6L (Seizure 6-like) gene, whose structure had been partially determined by the chromosome 22 sequencing project. We determined the full length cDNA sequence for the SEZ6L gene based on the genomic sequence for the SEZ6L locus using the GENSCAN program and the RT ± PCR method. The deduced SEZ6L protein was a transmembrane protein of 1024 amino acids with multiple domains involved in protein ± protein interaction and signal transduction. SEZ6L expression was detected in a variety of human tissues, including lung, while its expression was detected in 14 (30%) of 46 lung cancer cell lines examined. Missense mutations were detected in three (7%) of the 46 cell lines, and a 1 bp deletion in the polypyrimidine tract preceding exon 4 was detected in one (2%) of 46 primary lung cancers. Therefore, it is possible that genetic and/or epigenetic SEZ6L alterations are involved in the development and/or progression in a subset of lung cancer, although functional analysis of the SEZ6L gene as well as molecular analysis of other genes in the homozygously deleted region is necessary to understand the pathogenetic signi®cance of 22q deletions in human lung carcinogenesis. Oncogene (2000) 19, 6251 ± 6260.
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3 Third Department of Internal Medicine, Tokushima University, School of Medicine, 3-18, Tokushima-shi Japan Frequent allelic losses on chromosome 22q in small cell lung carcinomas (SCLCs) and advanced non-small cell lung carcinomas indicate the presence of tumor suppressor gene(s) on this chromosome arm. We detected a homozygous deletion at 22q12.1 in a SCLC cell line, Lu24. Cloning of the breakpoints of the Lu24 deletion revealed that the deletion was interstitial and 428, 131 bp in size. The deleted region contained the SEZ6L (Seizure 6-like) gene, whose structure had been partially determined by the chromosome 22 sequencing project. We determined the full length cDNA sequence for the SEZ6L gene based on the genomic sequence for the SEZ6L locus using the GENSCAN program and the RT ± PCR method. The deduced SEZ6L protein was a transmembrane protein of 1024 amino acids with multiple domains involved in protein ± protein interaction and signal transduction. SEZ6L expression was detected in a variety of human tissues, including lung, while its expression was detected in 14 (30%) of 46 lung cancer cell lines examined. Missense mutations were detected in three (7%) of the 46 cell lines, and a 1 bp deletion in the polypyrimidine tract preceding exon 4 was detected in one (2%) of 46 primary lung cancers. Therefore, it is possible that genetic and/or epigenetic SEZ6L alterations are involved in the development and/or progression in a subset of lung cancer, although functional analysisIntroduction Frequent allelic losses on chromosome 22q in small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) have been detected by several approaches, such as loss of heterozygosity (LOH) analysis (Shiseki et al., 1994 (Shiseki et al., , 1996 Kawanishi et al., 1997; Virmani et al., 1998; Stanton et al., 2000) , DNA ®ngerprinting (Anami et al., 2000; Yamada et al., 2000) , cytogenetic analysis (Testa et al., 1994; Mertens et al., 1997) and comparative genomic hybridization (Levin et al., 1994) , indicating the presence of tumor suppressor gene(s) on this chromosome. We previously reported that the incidence of LOH on 22q in advanced-stage NSCLC (460%) was signi®cantly higher than that in early-stage NSCLC (530%) (Shiseki et al., 1994 (Shiseki et al., , 1996 . In addition, SCLC, the most aggressive histological subtype of lung cancer, due to its early and wide dissemination, showed frequent (460%) LOH irrespective of clinical stages (Kawanishi et al., 1997) . Therefore, it is likely that inactivation of tumor suppressor gene(s) on chromosome 22q plays an important role in the acquisition of aggressive phenotypes in lung cancers.
Two known tumor suppressor genes, NF2 and SNF5/INI1, have been mapped to 22q12.2 and 22q11.2, respectively. The NF2 gene, which encodes a protein similar to the ERM (ezrin, radixin, and moesin) family of proteins linking cytoskeletal components with proteins in the cell membrane, was identi®ed as the gene responsible for neuro®bromatosis type 2 (NF2), an autosomal dominant disorder characterized by tumors of neural-crest origin (Rouleau et al., 1993; Trofatter et al., 1993) . Biallelic inactivation of the NF2 gene has been detected in NF2-related tumors, including schwannoma and meningioma (Ueki et al., 1999) . The hSNF5/INI1 gene, which encodes a member of the chromatin-remodeling SWI/SNF multiprotein complexes, was identi®ed as a gene frequently inactivated in malignant rhabdoid tumors by homozygous deletions and mutations (Versteege et al., 1998) . However, we and others showed that genetic and/or epigenetic alterations of these two genes are infrequent in SCLC and NSCLC (Sekido et al., 1995; Manda et al., 2000) . Therefore, the target gene(s) for 22q deletions in human lung cancer are still unknown. In addition, to our knowledge, common regions of chromosome 22q deletions have not been mapped in human lung cancer.
In the present study, we searched for homozygous deletions in 46 lung cancer cell lines to de®ne tumor suppressor loci on chromosome 22q. Fifteen microsatellite markers and 43 STS (sequence tagged site) markers, which were selected from the chromosome 22q sequence (Dunham et al., 1999) , were used for the screening of homozygous deletions. A homozygous deletion at chromosome 22q12.1 was detected in a SCLC cell line, Lu24. The Lu24 deletion was interstitial and 428,131 bp in size. The deleted region did not include any well-known genes, but included the SEZ6L gene and two putative genes, whose structure had been partially determined or predicted by the chromosome 22 sequencing project (Dunham et al., 1999) . We determined the structure of the full-length SEZ6L cDNA based on the data obtained by the GENSCAN gene prediction program analysis of the genomic sequence for the SEZ6L locus in conjunction with the RT ± PCR analysis. We then examined the genomic and expression status of the SEZ6L gene in human lung cancer cells to investigate the role of SEZ6L alterations in human lung carcinogenesis.
Results

Detection and characterization of a homozygous deletion in the Lu24 cell line
Homozygous deletions on 22q were searched for in 46 lung cancer cell lines, consisting of 14 SCLCs and 32 NSCLCs, using 58 STS markers dispersed in the 22q11.2-q13.3 region with intervals of 75 kb to 3.7 Mb. The STS markers consisted of 15 known microsatellite markers and 43 newly developed ones, which were derived from exons of 43 genes on 22q. The D22S310 locus mapped to 22q12.1 was not ampli®ed in the SCLC cell line Lu24, while the remaining 57 loci were ampli®ed in this cell line, indicating that Lu24 cells have a homozygous deletion of the region containing the D22S310 locus. On the other hand, all the 58 loci were ampli®ed in the remaining 45 cell lines.
The homozygous deletion at the D22S310 locus in the Lu24 cell line was con®rmed by multiplex PCR ( Figure  1a ).
Proximal and distal boundaries of the homozygous deletion in the Lu24 cell line were accurately mapped by the analysis of an additional 20 STS markers. The proximal breakpoint was mapped between the bk125H2sts#1 and D22S429 loci, while the distal one was mapped between exons 10 and 11 of the SEZ6L gene (Figure 1a ). Proximal and distal primers were designed to amplify the breakpoint junction of the deletion, and PCR was performed against genomic DNA from Lu24 cells and three normal lung tissues. A DNA fragment of approximately 2.0 kbp in size was ampli®ed from Lu24 DNA, but not from normal lung DNAs (Figure 1b) . Comparison of the sequence of the PCR fragment with that of genomic DNA revealed that the Lu24 deletion was a simple interstitial one of 428,131 bp from the chromosome 22q12.1 region (Figure 1c ). Since the same deletion was not observed in additional normal DNA samples of 50 unrelated individuals (100 alleles), the deletion was considered to be a somatic alteration rather than a genetic polymorphism.
Cloning and characterization of the SEZ6L gene
The sequence data of chromosome 22 (Dunham et al., 1999) indicated that the region deleted in the Lu24 cell line contains the SEZ6L gene consisting of 16 exons (GenBank TM accession number AB023144). In addition, two other genes have been predicted to be present in this region by a computer-based analysis of the genomic sequence (Dunham et al., 1999) . The SEZ6L gene was identi®ed as a gene homologous to the mouse SEZ-6 gene (Shimizu-Nishikawa et al., 1995) . The mouse SEZ-6 gene encodes a polypeptide with multiple domains possibly involved in cell adhesion and protein ± protein interaction (Shimizu-Nishikawa et al., 1995; Herbst and Nicklin, 1997) . Thus, we considered SEZ6L as a candidate tumor suppressor gene, since the SEZ6L gene aberrations possibly play a role in human lung carcinogenesis through alterations in cell ± cell interaction and/or intracellular signaling. Thus, we characterized the SEZ6L gene in the present study. The mouse SEZ-6 gene consists of 17 exons and encodes a transmembrane protein with an N-terminal signal sequence, while SEZ6L protein deduced from the deposited SEZ6L cDNA lacked an N-terminal signal sequence, in spite of the presence of a putative transmembrane region, indicating that the deposited SEZ6L cDNA was partial. Therefore, we analysed the genomic sequence corresponding to the deleted region in Lu24 (GenBank TM accession numbers AL080245, Z98949, AL079300, AL022337, AL080273, AL023513 and AL978460) by the GENSCAN gene prediction program. Then, in addition to the 16 exons already identi®ed, a candidate ®rst exon was detected in a CpG island where SacII and BssHII sites are clustered ( Figure 1a ). To con®rm that these 17 exons were transcribed as a transcript, we performed exonconnection PCR using human brain cDNA as a template with ®ve sets of primer pairs, which were predicted to amplify ®ve overlapping cDNA fragments. PCR products of the expected sizes were ampli®ed by PCR. Sequence analysis of the PCR products revealed that ampli®ed cDNA fragments overlapped each other and created a transcript of 3146 bp in size, which was derived from the predicted 17 exons. The SEZ6L cDNA contained an open reading frame (ORF) of 3072 bp encoding 1024 amino acids with a predicted Mw of 110 kD ( Figure 2a , deposited in GenBank TM accession number AB041736). Thus, it was concluded that the SEZ6L gene consisted of 17 exons and was dispersed within a 210 kb region ( Figure 1a ). Exon ± intron boundaries of all the exons agreed with the GT-AG rule.
The hydropathy pro®le of the deduced SEZ6L protein obtained by the SOSUI program analysis (Hirokawa et al., 1998) indicated the presence of two hydrophobic regions that probably function as a signal sequence and a transmembrane domain, respectively ( Figure 2a ). In addition, there were 11 potential Nlinked glycosylation sites in a possible extracellular domain. BLAST program analysis (Altschul et al., 1997) revealed that the structure of SEZ6L protein was similar to that of the mouse SEZ-6 protein ( Figure 2b ), and the level of amino acid identity between the human SEZ6L protein and the mouse SEZ-6 protein was 46.1%. SEZ6L protein contained ®ve short consensus repeats (SCRs) and two N-terminal halves of the CUB (Complement subcomponents C1r/C1s, Uegf, Bmpl) domain ( Figure 2c ). As in the case of mouse SEZ-6 (Herbst and Nicklin, 1997), SEZ6L has a putative short C-terminal cytoplasmic domain with the sequence of Asn-Pro-X-Tyr, which is a potential target for tyrosine phosphorylation by the Src family of tyrosine kinases ( Figure 2a) .
Northern blot hybridization analysis indicated that SEZ6L transcripts of 7.5 kb in size were expressed in adult and fetal brains but not in other tissues including lung (data not shown). However, RT ± PCR analysis indicated that the SEZ6L gene is expressed in diverse human tissues, including adult and fetal lungs ( Figure  3a ). In the course of cDNA cloning, we found that exons 12 ± 15 are alternatively spliced in human cells. That is, PCR products ampli®ed by a primer pair, encompassing exons 12 and 15, showed multiple bands in agarose electrophoresis (Figure 3b ). We subcloned PCR products into a plasmid vector by the TA cloning method and sequenced the inserts of 32 clones, which were randomly selected. The 32 clones represented nine dierent types of alternatively spliced transcripts ( Figure 3b , panels 1a ± 4a). These diered in the presence or absence of exons 13 and/or 14 and in the choice of the splice acceptor sites for exon 15 among three cryptic sites, which are 0, +3 and +6 bp of exon 15 ( Figure 2a ). Since another isoform ( Figure 3b , panel 4b), which was not present in the 32 clones, had been deposited in the database (GenBank TM accession number AL035545.1), it was indicated that at least 10 isoforms are transcribed from the SEZ6L gene, due to alternative splicing. The same reading frame was maintained in all the 10 isoforms identi®ed, although the absence of exons 13 and/or 14 caused the lack of a SCR from SEZ6L protein. Based on the sizes of PCR products and the contents of isoforms among the 32 subclones, types 1 and 2 were considered as being major transcripts (Figure 3b ).
Genetic alterations and expression of the SEZ6L gene in human lung cancers
Genomic PCR analysis revealed that exons 1 ± 10 of the SEZ6L gene were homozygously deleted, while exons 11 ± 17 were retained, in the Lu24 cell line (Figure 1a ). To examine whether the SEZ6L gene is a target of genetic alterations in human lung cancer cells, other than in the Lu24 cell line, the remaining 45 lung cancer cell lines and 46 surgical specimens of lung cancer were examined for genetic alterations of the SEZ6L gene. The entire coding region of the SEZ6L gene encompassing 17 exons was ampli®ed by PCR using 17 sets of intron-based primers. Genetic variations in exon 1 and exons 3 ± 17 were examined by SSCP analysis followed by direct sequencing, while those in exon 2 were examined by direct sequencing. Thirteen dierent types of nucleotide substitutions were detected in lung cancer cell lines and surgical specimens ( Figure 4a , Table 1 ). Seven of them, G178C, G563A, G664A, G1290T, A1381G, G1576A, G1889T, were non-synonymous (associated with amino acid change) substitutions, while the remaining six consisted of ®ve synonymous (silent) substitutions and an intronic substitution.
Among the seven non-synonymous substitutions, G563A was detected as a homozygous substitution in a cell line, while G178C and G1889T, respectively, were detected as heterozygous substitutions in a single cell line. These substitutions were not detected in surgical specimens and normal DNA samples of 50 unrelated individuals (100 alleles), therefore, they were Oncogene 22q12.1 homozygous deletion in human lung cancer M Nishioka et al likely to be somatic mutations. However, since the corresponding normal tissue DNAs for those cell lines were not available, the possibility that the substitutions were rare polymorphisms could not be excluded. The remaining four non-synonymous substitutions, G664A, G1290T, A1381G and G1576A, were detected in both of the DNA samples from primary tumors and corresponding normal tissues. Therefore, they were considered as genetic polymorphisms. The ®ve synonymous substitutions were also considered as being genetic polymorphisms, although the presence of the same substitutions in normal tissues was con®rmed in four of them. The intronic substitution, which had occurred in a surgical specimen of SCLC, S181T, was a homozygous one base deletion at the 73*75 nucleotide before the splice acceptor site of exon 4. The deletion was somatic, since it was not detected in the corresponding normal lung tissue (Figure 4a) . Expression of the SEZ6L gene in human lung cancer cell lines was assessed by RT ± PCR analysis. SEZ6L expression was detected in 14 (30%) of 46 lung cancer cell lines ( Figure 4b , Table 2 ), and these 14 cell lines expressed multiple alternatively spliced isoforms with dierent ratios (Figure 3b ). SEZ6L expression was preferentially detected in SCLCs, and the dierence in the incidence of SEZ6L expression between SCLC (9/14) and NSCLC (5/32) was statistically signi®cant (P=0.0018, Fisher's exact test).
SEZ6L was expressed in the NCI-H526 and NCI-H23 cell lines with heterozygous SEZ6L missense mutations, while it was expressed neither in the EBC-1 cell line with a homozygous missense mutation nor in the Lu24 cell line with a homozygous deletion of the SEZ6L gene. SEZ6L expression was further examined in four primary lung tumors, a primary culture of bronchial epithelial cells, SAEC, a bronchial epithelial cell line, tpc16B, and a lung ®broblast cell line, WI-38 (Figure 4c ). SEZ6L expression was detected in two of the four tumors. SEZ6L expression was detected in the cultured bronchial epithelial cells, but not in the bronchial epithelial cell line and the lung ®broblast cell line.
Discussion
In spite of several lines of evidence that chromosome 22q contains tumor suppressor gene(s) for lung cancer, target regions for the 22q deletions in lung cancer have not been mapped to date. Therefore, we searched for homozygous deletions using 58 DNA markers dispersed on chromosome 22q. A homozygous deletion causing the lack of the genomic segment of 428,131 bp of the 22q12.1 region was detected in a SCLC cell line, Lu24. Homozygous deletions are often observed at known tumor suppressor loci , therefore, it is possible that the deleted region in Lu24 cells contains a tumor suppressor gene. Thus, we further searched for genes mapped to the region of the homozygous deletion in Lu24 cells. We found that the homozygous deletion in Lu24 cells disrupted the SEZ6L gene. The structure of the SEZ6L gene has been partially determined by the eorts of the human chromosome 22 sequencing project, and it was indicated that SEZ6L is a homolog of the mouse SEZ-6 gene. Thus, we cloned and characterized the full-length cDNA for the SEZ6L gene. It was con®rmed that this gene encodes a polypeptide homologous (46.1%) to the mouse SEZ-6 protein.
Since a partial cDNA sequence, HFBDF14, encoding a polypeptide showing 91.7% homology with mouse SEZ-6 protein, has been identi®ed (Shimizu-Nishikawa et al., 1995) , it is likely that HFBDF14 is the human counterpart of the SEZ-6 gene and that SEZ6L is a homolog of the mouse SEZ-6 gene. Similar to mouse SEZ-6, deduced human SEZ6L protein has a transmembrane domain, ®ve SCRs, two N-terminal halves of the CUB domain, and a cytoplasmic region. The SCR repeat motif and the N-terminal half of the CUB domain are present in the complement-related proteins, and both protein motifs are thought to be involved in signaling as well as structural associations. SEZ6L has a short C-terminal cytoplasmic domain with the sequence of Asn-Pro-X-Tyr. This motif is a potential target for tyrosine phosphorylation by Src family proteins. Phosphorylation of this motif is believed to cause the association of the motif with signal transduction adaptor molecules, Shc (Src homologous and collagen) and/or IRS-1 (insulin receptor substrate-1), and to relay the signals (Sudol, 1998) . SEZ6L was abundantly expressed in the brain, and also expressed in a variety of human tissues, including lung epithelial cells. Therefore, SEZ6L protein is considered to be a transmembrane protein functioning as an intracellular a b Figure 3 Expression of the SEZ6L gene. (a) SEZ6L expression in normal human tissues detected by RT ± PCR analysis. RT ± PCR ampli®cation was performed for 30 and 35 cycles using a set of primer pairs, SEZ6L-set6F and SEZ6L-set6R. GAPDH (25 cycles) was analysed to standardize the amounts of RNA. (b) Alternative splicing of the SEZ6L gene. Upper: RT ± PCR analysis of the SEZ6L gene in lung cancer cell lines and normal lung and brain. PCR ampli®cation was performed using a set of primer pairs, SEZ6Lsp-s and SEZ6Lsp-as, whose sequences were derived from exons 12 and 15, respectively Oncogene 22q12.1 homozygous deletion in human lung cancer M Nishioka et al Figure 4 Mutations and expression of the SEZ6L gene in human lung cancer. (a) Nucleotide substitutions of the SEZ6L gene. Nucleotide changes are apparent when compared to unrelated normal DNA samples (EBC1 and H23) or to a matched normal DNA sample (S181T). In EBC1 and S181T, histograms for sequencing in the reverse direction are shown. The mutated nucleotides are underlined. (b) SEZ6L expression in human lung cancer cell lines detected by RT ± PCR analysis. RT ± PCR ampli®cation was performed for 35 cycles using two sets of primer pairs, SEZ6L-set3F and SEZ6L-set3R, and SEZ6L-set6F and SEZ6L-set6R. GAPDH (25 cycles) was analysed to standardize the amount of RNA of each sample. SCC; small cell lung carcinoma, AdC; adenocarcinoma, AdSqC; adenosquamous carcinoma, SqC; squamous cell carcinoma, LCC; large cell carcinoma. (c) SEZ6L gene expression in cancerous and non-cancerous lung cells detected by RT ± PCR. RT ± PCR ampli®cation was performed for 40 cycles using a set of primer pair, SEZ6L-set6F and SEZ6L-set6R. GAPDH (25 cycles) was analysed to standardize the amount of RNA of each sample 22q12.1 homozygous deletion in human lung cancer M Nishioka et al signal transducer via protein ± protein interactions in a variety of human cells. We then examined the genetic and expression status of the SEZ6L gene in 46 lung cancer cell lines and 46 surgical specimens of lung cancer. In addition to the homozygous deletion in the Lu24 cell line, 13 dierent types of nucleotide substitutions were identi®ed, and seven of them were non-synonymous. Three of the seven non-synonymous substitutions, which were detected in three dierent cell lines, NCI-H526, EBC1 and NCI-H23, were considered as somatic mutations. Especially, a missense substitution at codon 630, observed as heterozygous mutation in NCI-H23, caused substitution of a relatively conserved amino acid, glycine, in the second N-terminal half of the CUB domain, to valine. Thus, it is possible that the nonsynonymous substitutions of the SEZ6L gene have some eects on the physiological function of the SEZ6L protein. A homozygous 1 bp deletion in the polypyrimidine tract preceding exon 4 was also detected in a case of primary SCLC. The polypyrimidine tract is critical for appropriate splicing (Roscigno et al., 1993; Norton, 1994) , and mutations in the polypyrimidine tract often cause abnormal splicing (Wilmotte et al., 1999; Magnusson et al., 2000) . Therefore, it is possible that the 1 bp deletion also leads to abnormal splicing of the SEZ6L gene. However, we could not examine whether this mutation caused abnormal splicing because mRNA from this specimen was not available. These results indicated that the SEZ6L gene is genetically altered in a subset of lung cancer.
Although the SEZ6L gene was expressed in human lung tissue, SEZ6L expression was detected only in a portion (14/46, 30%) of the lung cancer cell lines examined. Loss of SEZ6L expression was also observed in the primary lung cancers. At present, the molecular mechanisms for the dierential SEZ6L expression in lung cancer cells are unclear. Loss or reduction of SEZ6L expression could be caused by epigenetic changes, such as hypermethylation of the CpG island, as in the cases of the VHL and p16 genes (Herman et al., 1994; Merlo et al., 1995; Hamada et al., 1998) , or genetic alterations in the promoter region and intron sequences. We preliminarily examined the eect of 5-aza-2' deoxycytidine on SEZ6L expression in lung cancer cell lines without SEZ6L expression, however, re-expression of the SEZ6L gene was not observed in these cell lines (data not shown). Therefore, hypermethylation is unlikely to be a cause of the loss of SEZ6L expression. It is also possible that the status of SEZ6L expression in lung cancer cell lines re¯ects that in their precursor cells, since SEZ6L expression was observed in one of the two cultured lung epithelial cells. Dierential expression was also observed between SCLC and NSCLC. However, since precursor cells for lung cancer are still obscure at present, more detailed analysis of SEZ6L expression in cancerous and non-cancerous lung tissues will be necessary to clarify the mechanism(s) for the dierential expression of SEZ6L in lung cancer cells.
The results of the present study indicated that SEZ6L is genetically altered in a small subset of lung cancer in spite of the fact that LOH on 22q is observed in a large portion of lung cancer. Therefore, gene(s) on 22q, other than SEZ6L, could be a major tumor suppressor gene inactivated by 22q deletions. Interestingly, two other genes have been predicted to be present in the homozygously deleted region of the Lu24 cell line by a computer-based analysis of the genomic sequence of this region (Dunham et al., 1999) . Therefore, we are currently isolating full-length cDNA clones for these two genes to investigate whether Non-synonymous substitutions, which were not detected in DNA from non-cancerous tissues, and a somatic deletion; b Non-synonymous substitutions, which were detected in DNA from non-cancerous tissues, and synonymous substitutions; c Nucleotide substitutions were also detected in the correpsonding normal tissues; alterations of these two genes are involved in human lung carcinogenesis. Recently, it was reported that the EP300 gene at 22q13, encoding a histone acetyltransferase that regulates transcription via chromatin remodeling, is mutated in a subset of lung cancer and several other cancers (Gayther et al., 2000) . Therefore, it is likely that 22q contains several genes that can be targets for genetic alterations. Such a prediction is also supported by the fact that LOH on 22q occurs frequently in several types of human cancers and multiple regions have been mapped as common regions of LOH on 22q (Ueki et al., 1999; Castells et al., 2000) . Therefore, further investigations on the alterations of genes and regions on 22q are necessary for the elucidation of the pathogenetic signi®cance of chromosome 22q deletions in the development and/or progression of lung cancer and other cancers. Lastly, we cloned the breakpoint junctions of the Lu24 deletion. Up to the present, breakpoint junctions of chromosomal deletions have been cloned from several human cancer cells (Canning and Dryja, 1989; Pomykala et al., 1994; Kohno et al., 1996; Inoue et al., 1997) . DNA sequences surrounding the deletion breakpoints often contain short direct repeats and the breakpoint junctions of the rearranged DNAs have 1 ± 6 bp overlaps of germline sequences. Based on these results, it has been hypothesized that chromosomal deletions occur through short homology-mediated recombination after double strand breaks (Chen et al., 1998; Ueda et al., 1999) . However, there were no direct repeats in the sequence surrounding the breakpoints for Lu24 deletion, and germline sequences were not overlapped in the junction (Figure 1c) . A similar feature was also observed in the breakpoint junction of a chromosome 3p21.3 deletion in a case of breast cancer (Sekido et al., 1998) . The present results suggest that there are several molecular mechanisms generating genomic deletions. Information on the sequence at the breakpoint junction of the Lu24 deletion would be helpful to understand the mechanism underlying the occurrence of genomic deletions during carcinogenesis.
Materials and methods
Samples
Forty-six lung cancer cell lines consisting of 14 SCLCs and 32 NSCLCs were used in this study. The 14 SCLC cell lines were NCI-H69, NCI-H82, NCI-H209, NCI-H526, NCI-H774, NCI-H841, N417, RERF-LCMA, Lu24, Lu134, Lu135, Lu139, SBC-5, and MS18, while the 32 NSCLCs consisted of 20 adenocarcinomas (A427, A549, PC3, PC7, PC9, PC14, RERF-LCOK, VMRC-LCD, ABC1, LCMS, NCI-H23, NCI-H322, NCI-H441, Ma1, Ma10, MA12, Ma17, Ma24, Ma26 and Ma29), ®ve squamous cell carcinomas (PC10, LC1-Sq, EBC1, NCI-H157 and NCI-H520), six large cell carcinomas (PC13, Lu99, Lu65, NCI-H1155, Ma2 and Ma25), one adenosquamous cell carcinoma (NCI-H596) (Hamada et al., 1998) . Forty-six surgical specimens (16 SCLCs and 30 NSCLCs) of lung tumors and adjacent noncancerous tissues were obtained from patients with NSCLC and SCLC who were treated at the National Cancer Center Hospital, Tokyo. Eleven primary tumors and ®ve metastases were obtained from 16 patients with SCLC, while 15 primary lung tumors and 15 brain metastases were obtained from 30 patients with NSCLC. NSCLCs consisted of 19 adenocarcinomas, ®ve squamous cell carcinomas, four large cell carcinomas and two adenosquamous cell carcinomas. The material to be analysed was selected by a pathologist to ensure that the samples were macroscopically entirely tumorous and chosen from an area devoid of necrotic tissue. Tumor and normal tissue were frozen and stored at 7708C until DNA extraction. High-molecular-weight DNA was prepared from the cell lines, tumors and adjacent noncancerous tissues, as described previously . High-molecular-weight DNA prepared from noncancerous tissues of 50 unrelated patients with several cancers was also used in this study. Poly (A) + RNA was prepared from 46 lung cancer cell lines, a primary culture of normal human small airway epithelial cells (SAEC) (Clonetics, Walkersville, USA), a bronchial epithelial cell line (tpc16B) and a lung ®broblast cell line (WI-38) by the Fast Track mRNA isolation kit (Invitrogen, Carlsbad, CA, USA). Total RNA was prepared from primary tumors obtained from four NSCLC patients who were treated at the National Cancer Center Hospital, using TRIZOL Reagent (Life Technologies, Inc., Tokyo, Japan). Poly (A) + RNA from human normal tissues was purchased from CLONTECH Laboratories Japan Ltd. (Tokyo, Japan). Randomly primed cDNAs were reversetranscribed from 0.5 mg mRNAs or 10 mg total RNAs by using SuperScriptII RNase H Reverse Transcriptase (Life Technologies, Inc.) according to the supplier's protocol.
Screening for homozygous deletions
Homozygous deletions were examined by PCR ampli®cation of STSs on chromosome 22q. STSs used for the screening of homozygous deletions were 15 microsatellite markers, D22S264, D22S301, D22S345, D22S310, D22S275, D22S280, D22S685, D22S283, IL2RB, D22S284, D22S276, D22S270, D22S282, D22S274 and D22S526 (according to Genome Data Base) and 43 STSs developed, based on the genomic sequences of chromosome 22q (Dunham et al., 1999) . The novel STSs were derived from exon 1 or 2 of 43 genes (BID, TOP3b, D87003.1, BCRL4, BCR, BCRL6, MN1, ESWR1, RFPL1, OSM, PES1, bK963H5.1, LIMK2, DRG1, RFPL2, RFPL3, TIMP3, MCM5, RBM9, bK212A2.1, MYH9, NCF4, IL2RB, PSCD4, SH3BP1, PLA2G6, dj449O17.1, DDX17, GTPBP, TAB1, GRAP2, ST13, RBX1, EP300, TROB2, NHP2L1, TCF20, dJ437M21.2, dJ100N22.1, ARHGAP8, SMC1L2, PPARA and CELSR1). Detailed information on these STSs can be obtained upon request. PCR was carried out by using 50 ng of genomic DNA as a template in a total volume of 20 ml reaction mixture containing 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 1.5 mM MgCl 2 300 nM of each primer, 200 mM of each deoxynucleotide triphosphate, and 0.5 units of Taq DNA polymerase (Amersham Pharmacia Biotech, Tokyo, Japan). PCR conditions were 958C for 1 min, 558C or 608C for 1 min and 728C for 2 min for 30 cycles, followed by 728C for 10 min. PCR products were fractioned on a 3% agarose gel and stained with ethidium bromide. Homozygous deletions were con®rmed by comparative multiplex PCR using the TP53 (exons 7 ± 8) locus as a reference, as described previously .
Cloning of the breakpoint junction of the homozygous deletion
Sixteen known STSs (D22S926, D22S538, D22S650, D22S538, D22S429, D22S1148, D22S574, D22S642, D22S46, D22S564, D22S351, D22S300, D22S560, D22S1, D22S193, and a298yb5) and four novel STSs developed, based on the genomic sequences of chromosome 22q (Dunham et al., 1999) , were analysed for Lu24 in order to narrow down the site of the centromeric and telomeric breakpoints of the Lu24 deletion. The primer pair, bk125H2sts#1-F, 5'-AGTTTCTTGTCCCTTTACATTGCT-3' and 11as, 5'-CCTAGAGGAAGGAAACAAGAC-3', was used for the cloning of the 2092 bp fragment containing the 22q12.1 homozygous deletion in human lung cancer M Nishioka et al breakpoints of the Lu24 deletion. PCR fragments were puri®ed by using a QIA quick-spin PCR puri®cation kit (QIAGEN). DNA sequencing was performed bidirectionally by using Thermo Sequence dye terminator cycle sequencing pre-mix kits (Amersham Pharmacia Biotech) and the ABI 373S DNA Sequence System (PE Biosystems Japan, Tokyo, Japan). The primer pair, bk125H2#2-F, 5'-CGGGGTTTT-ATACCCTCATG-3', and 11as, was used for the ampli®ca-tion of a 758 bp genomic DNA fragment containing the Lu24 breakpoints to examine whether the same allele for the interstitial deletion was present in normal DNA samples of 50 unrelated individuals.
Isolation of full-length human SEZ6L cDNA
Genome DNA sequences obtained from Genbank TM (AL080245, Z98949, AL079300, AL022337, AL080273, AL023513 and AL978460) were analysed by the GENSCAN gene-prediction program (Burge and Karlin, 1997) . Predicted exons were connected by exon-connection PCR using human brain cDNA as a template. RT ± PCR ampli®cation was performed at 958C for 1 min, 608C for 1 min and 728C for 2 min for 35 cycles, followed by 728C for 10 min using ®ve primer sets, SEZ6L-set1F (5'-TCCGCGCCCCCTGCAG-3') and SEZ6L-set1R (5'-AGCACTTCCGCCGACTGTGA-3'), SEZ6L-set2F (5'-ATCTCGCTGTTCCTCGCTCTG-3') and SEZ6L-set1R, SEZ6L-set3F (5'-TCTTCCCGAGGGAGAT-GCTA-3') and SEZ6L-set3R (5'-AGTCGCTGGAGTCAA-TGTAC-3'), SEZ6L-set4F (5'-CTGATGGACAAAGGTGA-GAATG-3') and SEZ6L-set4R (5'-GCAGGTGAACTCCAC-TATAGT-3') or SEZ6L-set5F (5'-ACTACATCCGACCC-GACCTA-3') and SEZ6L-set5R (5'-TCCCCTTCTCAAG-TGTAGCT-3'). The presence of splicing variants in SEZ6L mRNA was examined by RT ± PCR analysis using a primer pair, SEZ6Lsp-s (5'-CACCATCCAATACACCTGC-3') and SEZ6Lsp-as (5'-TGAAGATAGCCAGGGCCATG-3'). Ampli®ed cDNA fragments were either directly sequenced or subcloned into the pGEM T-Easy vector (Promega, Madison WI) prior to sequencing. PCR fragments and plasmids containing PCR fragments were puri®ed and sequenced in both directions as described in Cloning of the breakpoint junction of the homozygous deletion section.
RT ± PCR analysis
One microliter of cDNA conversion mixture was ampli®ed under the following conditions; 958C for 1 min, 608C for 1 min, 728C for 1.5 min for 30, 35 or 40 cycles (for SEZ6L) and for 25 cycles (for GAPDH), followed by 728C for 10 min. Two sets of primers used in this study, SEZ6L-set3F and SEZ6L-set3R and, SEZ6L-set6F, 5'-TACATCACAAGATG-TCGCTA-3' and SEZ6L-set6R, 5'-TTAGATAGAAACCT-CATACTCTCTG-3', were used for the ampli®cation of 790 bp (nucleotides 99 ± 889) and 144 bp (nucleotides 2932 ± 3075) SEZ6L cDNA fragments, and another set of primers, 5'-AAGGTCATCCATGACAAC-3' and 5'-CACCCTGTTG-CTGTAGCCA-3', was used for the GAPDH gene (nucleotides 544 ± 1032 of Genbank TM M33197). The SEZ6L and GAPDH primer pairs were designed to amplify cDNA fragments encompassing two adjacent exons. The PCR products were electrophoresed on a 2.0% agarose gel and stained with ethidium-bromide.
Mutation analysis of the SEZ6L gene
Seventeen exons of the SEZ6L gene were ampli®ed for SSCP analysis (exons 1 and 3 ± 17) or direct sequencing (exon 2) with 17 sets of primers designed to amplify each exon together with some nucleotides¯anking the 5' and 3' intron
